Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health
Farmers Insurance
Deloitte
Cerilliant
McKesson
Federal Trade Commission
Merck
Accenture

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,703,177

« Back to Dashboard

Which drugs does patent 8,703,177 protect, and when does it expire?

Patent 8,703,177 protects BUNAVAIL and is included in one NDA.

This patent has nineteen patent family members in fourteen countries.
Summary for Patent: 8,703,177
Title:Abuse-resistant mucoadhesive devices for delivery of buprenorphine
Abstract: The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized.
Inventor(s): Finn; Andrew (Raleigh, NC), Vasisht; Niraj (Cary, NC)
Assignee: BioDelivery Sciences International, Inc. (Raleigh, NC)
Application Number:13/590,094
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,703,177
Patent Claim Types:
see list of patent claims
Device;

Drugs Protected by US Patent 8,703,177

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bdsi BUNAVAIL buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL 205637-001 Jun 6, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bdsi BUNAVAIL buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL 205637-002 Jun 6, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bdsi BUNAVAIL buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL 205637-003 Jun 6, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,703,177

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012296346 ➤ Try a Free Trial
Australia 2018200402 ➤ Try a Free Trial
Brazil 112014003651 ➤ Try a Free Trial
Canada 2845634 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Queensland Health
AstraZeneca
Teva
McKinsey
Express Scripts
Chinese Patent Office
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.